Kim Bo Kyoung, Canonica Jérémie, Roudnicky Filip, Westenskow Peter D
Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Methods Mol Biol. 2022;2475:259-274. doi: 10.1007/978-1-0716-2217-9_19.
Difficulties with poor reproducibility and translatability of animal model-based research, along with increased efforts to abide by the 3Rs tenet of animal welfare, are driving demand for more relevant human cellular systems. This is especially true for central nervous system (CNS) vasculatures with specialized properties and barriers, namely the blood-brain and blood-retinal barriers (BBB and BRB, respectively) which are difficult to model in vitro. The BBB and BRB protect neurovascular units by regulating nutrient homeostasis, maintaining local ion levels, protecting against exposure from circulating toxins and pathogens, and restricting passage of peripheral immune factors. In this manuscript, we will describe transgenic and pharmacological-based protocols to generate relevant BBB and BRB models both from human pluripotent stem cell-derived endothelial cells (hPSC-ECs) and from primary human umbilical vein endothelial cells (HUVECs). When followed, researchers can expect to generate well-characterized, anatomical and functional BBB and BRB EC monolayers in 36-48 h that are stable up to 90 h. The ability to generate more relevant BBB and BRB EC cultures will improve drug discovery efforts and inform future therapies for neurovascular disorders.
基于动物模型的研究存在可重复性差和可转化性低的问题,同时为遵守动物福利的3R原则所做的努力不断增加,这推动了对更具相关性的人类细胞系统的需求。对于具有特殊性质和屏障的中枢神经系统(CNS)血管系统而言尤其如此,即血脑屏障和血视网膜屏障(分别为BBB和BRB),它们很难在体外进行模拟。血脑屏障和血视网膜屏障通过调节营养物质稳态、维持局部离子水平、防止循环毒素和病原体的暴露以及限制外周免疫因子的通过来保护神经血管单元。在本手稿中,我们将描述基于转基因和药理学的方案,以从人多能干细胞衍生的内皮细胞(hPSC-ECs)和原代人脐静脉内皮细胞(HUVECs)生成相关的血脑屏障和血视网膜屏障模型。按照这些方案进行操作,研究人员有望在36-48小时内生成特征明确、具有解剖学和功能的血脑屏障和血视网膜屏障内皮细胞单层,并且这些单层在长达90小时内保持稳定。生成更具相关性的血脑屏障和血视网膜屏障内皮细胞培养物的能力将改善药物研发工作,并为未来神经血管疾病的治疗提供参考。